Drug Profile

Aflibercept biosimilar - Shanghai Jingze Biotechnology

Alternative Names: JZB 07; JZB-05

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Jingze Biotechnology
Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

22 Dec 2025 Preclinical trials in Diabetic macular oedema in China (Intravitreous)
22 Dec 2025 Preclinical trials in Wet age-related macular degeneration in China (Intravitreous)
19 Dec 2025 Shanghai Jingze Biotechnology plans to file an IND application with the NMPA in China in 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com